Tas Sander W, Baeten Dominique L P
Department of Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam, Meibergdreef 9, 22600, 1105, Amsterdam, The Netherlands.
Department of Experimental Immunology, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Methods Mol Biol. 2016;1371:143-55. doi: 10.1007/978-1-4939-3139-2_9.
The treatment of immune-mediated inflammatory diseases (IMIDs) has dramatically improved over the last two decades by the development of a series of targeted biological therapies. This paper focuses on new developments in the treatment of IMIDs. In particular, we discuss how different ways of targeting the same mediators can lead to different efficacy and safety profiles, using B cell targeting as example. In addition, we discuss the emerging field of 'small molecules' that target specifically intracellular processes related to cytokine signaling, cell activation, cell migration, and other processes relevant to tissue inflammation.
在过去二十年中,通过一系列靶向生物疗法的发展,免疫介导的炎症性疾病(IMIDs)的治疗取得了显著进展。本文重点关注IMIDs治疗的新进展。特别是,我们以B细胞靶向为例,讨论针对相同介质的不同方式如何导致不同的疗效和安全性。此外,我们还讨论了新兴的“小分子”领域,这些小分子专门针对与细胞因子信号传导、细胞活化、细胞迁移以及与组织炎症相关的其他过程有关的细胞内过程。